Engene Holdings INC 8-K filings

enGene Therapeutics Inc. hosted a KOL event on August 11, 2026, to present market research on non-muscle-invasive bladder cancer (NMIBC) and discuss its investigational therapy, detalimogene.

enGene Therapeutics Inc. has released an updated corporate presentation on July 17, 2026, detailing the progress of its lead investigational drug, detalimogene voraplasmid, for Non-Muscle Invasive Bladder Cancer (NMIBC).

enGene Therapeutics announces board leadership changes and outlines upcoming regulatory and commercial plans for its lead drug candidate, detalimogene.

enGene Therapeutics Inc. files an 8-K/A to update its workforce reduction plan, detailing new equity retention awards and revised cost estimates.

enGene Therapeutics announced a 50% workforce reduction and executive departures to streamline operations and preserve cash while advancing its lead drug candidate, detalimogene.

enGene Therapeutics Inc. reports strong shareholder turnout and overwhelming support for director elections and auditor appointment at its 2026 Annual General Meeting.

enGene Therapeutics announced updated interim clinical data from its Phase 2 LEGEND trial for detalimogene voraplasmid, showing a 54% complete response rate at any time.

enGene Therapeutics Inc. announced its corporate name change to reflect its transition towards becoming a commercial organization, targeting a 2027 launch for its detalimogene voraplasmid.

enGene Holdings Inc. has amended its loan agreement with Hercules Capital, increasing its term loan facility to $125 million and extending the maturity date to 2030, providing significant capital for its strategic initiatives.

enGene Holdings Inc. announced an expanded $125 million debt facility with Hercules Capital to fund the development and potential commercialization of its bladder cancer therapy, detalimogene.

enGene Holdings Inc. announced full year 2025 financial results and significant progress in its pivotal LEGEND trial for high-risk bladder cancer, extending its cash runway into 2H 2028.

enGene Holdings Inc. announced the pricing of a $130 million public offering of common shares and pre-funded warrants, with an option for underwriters to purchase additional shares.

enGene Holdings Inc. reports improved preliminary efficacy and favorable tolerability for its lead drug candidate, detalimogene, in high-risk bladder cancer patients following a protocol amendment.

enGene Holdings Inc. amended Ronald H. W. Cooper's employment agreement, increasing his change-in-control termination bonus multiplier.

enGene Holdings Inc. announced the committee assignments for newly appointed directors Philip Astley-Sparke and Michael Heffernan, effective October 2, 2025.

enGene Holdings Inc. announced the appointment of Dr. Hussein Sweiti as Chief Medical Officer, strengthening its clinical development and regulatory capabilities for detalimogene.

enGene Holdings Inc. announced its third-quarter 2025 financial results, highlighted by target enrollment in its pivotal LEGEND trial and RMAT designation for detalimogene.

enGene Holdings Inc. announced it achieved target enrollment for the pivotal cohort of its LEGEND trial for detalimogene voraplasmid, a non-viral gene therapy for high-risk bladder cancer, with a Biologic License Application submission now planned for the second half of 2026.

enGene Holdings Inc. announced significant board and management appointments, including three new directors and key promotions, to bolster its strategic transition towards the planned commercialization of its lead investigational therapy, detalimogene.

enGene Holdings Inc. announced its financial results for the second quarter ended April 30, 2025, and provided a business update, highlighting progress with the LEGEND study and BLA filing plans.

enGene Holdings Inc. shareholders overwhelmingly approved the 2025 Employee Stock Purchase Plan, reserving 2 million common shares for employee acquisition, alongside the re-election of directors and appointment of auditors at its Annual General Meeting on June 10, 2025.

enGene Holdings Inc. has announced that its wholly-owned subsidiary, enGene USA, Inc., has entered into a new five-year and five-month office lease for approximately 26,335 square feet in Boston, Massachusetts, with the parent company providing an unconditional guarantee for all lease obligations.

enGene Holdings Inc., a clinical-stage genetic medicines company, announced the resignation of Dr. Raj S. Pruthi as Chief Medical Officer, effective June 16, 2025, with his responsibilities to be reallocated internally.

enGene Holdings Inc. announced its first quarter 2025 financial results, highlighting progress with the LEGEND study and a cash runway into 2027.

enGene Holdings Inc. has entered into an agreement with Jefferies LLC to potentially sell up to $100 million of its common shares through an at-the-market offering.

enGene Holdings amended its loan agreement to reallocate funds and announced its full year 2024 financial results, highlighting a strong cash position and progress in its clinical trials.

enGene Holdings Inc. has successfully raised approximately $60 million through a private placement to further the development of its lead drug candidate and expand its technology platform.

enGene Holdings Inc. has announced several executive leadership changes, including the appointment of a new Chief Technology Officer and a transition of the Chief Technology Officer to Chief Scientific Officer.

enGene Holdings reported promising preliminary data from its LEGEND study, showing a 71% complete response rate at any time for its bladder cancer treatment, detalimogene.

enGene Holdings Inc. announced its third quarter 2024 financial results, highlighting a cash runway into 2027 and the upcoming release of preliminary LEGEND study data.